09:45 AM EDT, 07/10/2024 (MT Newswires) -- Eagle Pharmaceuticals ( EGRX ) said in a regulatory filing Wednesday that it has agreed to pay Curia Global $26.5 million to settle a dispute over their Vasopressin commercial supply agreement.

As part of the settlement, Curia Global has discontinued its lawsuit against Eagle in the New York Supreme Court over their Pemfexy master development and supply agreement, Eagle said. The Pemfexy master supply agreement remains in effect, the company said in its filing.

Eagle said the settlement, signed on July 3, is not an admission of liability or wrongdoing by either company.

Under the settlement, Eagle will make the payments in installments, with $10 million already paid on July 5, according to the regulatory filing. Eagle will pay $10 million in February and $6.5 million before July 7, 2025, the company added.

Price: 6.08, Change: +0.01, Percent Change: +0.16